PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.
Christian Kurzeder
Honoraria - Roche
Other Remuneration - Roche
Jose Maria Del Campo
No relevant relationships to disclose
Patricia Pautier
Consultant or Advisory Role - AstraZeneca; PharmaMar; Roche
Felix Hilpert
Consultant or Advisory Role - Roche
Honoraria - Roche
Angiolo Gadducci
No relevant relationships to disclose
Petronella Ottevanger
No relevant relationships to disclose
Domenica Lorusso
Consultant or Advisory Role - Roche
Research Funding - Roche
Ignace Vergote
Consultant or Advisory Role - Roche (U)
Research Funding - University of Leuven
Isabel Bover
No relevant relationships to disclose
Michel Fabbro
No relevant relationships to disclose
Frederik Marmé
Honoraria - Amgen; Celgene; Novartis; Roche
Other Remuneration - Amgen; Celgene; Novartis; Roche
Yolanda Garcia
No relevant relationships to disclose
Frédéric Selle
No relevant relationships to disclose
Martina Gropp-Meier
No relevant relationships to disclose
Beatriz Pardo
No relevant relationships to disclose
Ulrich Freudensprung
Employment or Leadership Position - Roche
Ru-Amir Walker
Employment or Leadership Position - Roche
Stock Ownership - Roche
Antonio Gonzalez-Martin
No relevant relationships to disclose